Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055419 · ClinicalTrials.gov registry record · Phase 2
A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 744
- Enrollment target
NCT00055419: Completed Phase 2 study, sponsored by Eli Lilly and Company.
NCT00055419 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 744 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (459% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00055419, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 744 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.
Interventions
- BIOLOGICAL Cetuximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 744 participants |
| Start Date | 2003-02 |
| Est. Completion | 2004-08 |
| Phase | Phase 2 |
What the finished NCT00055419 record still lists
NCT00055419 is an interventional study that assigns participants to a tested intervention. The registered 744 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (459% higher).
The record links to 0 conditions, and to 1 intervention - of which Cetuximab is the first listed.
NCT00055419 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00055419 about?
NCT00055419 is a clinical study titled "A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer". The purpose of this clinical research study is to learn about the safety of cetuximab in patients with stage IV colorectal cancer, and who may benefit from cetuximab.
What is the current status of trial NCT00055419?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 744 participants. The study started on 2003-02. Estimated completion is 2004-08.
What interventions are being tested in trial NCT00055419?
The interventions under investigation include: Cetuximab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00055419?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00055419's enrollment target sits among peer trials
744 44th of 2000 higher than 1,957 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05619185 · 744 participants · NA
A SMART Evaluation of an Adaptive Web-based AUD Treatment for Service Members and Their Partners
- NCT06417814 · 744 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- NCT07046351 · 744 participants · NA
weSIPsmarter: Evaluating a Digital Health Intervention Aimed at Reducing Sugary Drinks Among Rural Head Start Preschoolers and Their Parents
- NCT07199569 · 744 participants · Phase 2
Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia